Press releases

Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting

Fri, Sep 24 2021, 15:15 GMT+0200 | Press release

The company has developed a CE-marked medical device for reduction of blood group A and blood group B specific antibodies (UBP-product).

Massive bleeding is one of the leading causes of death in severe trauma. Evidence is growing suggesting that transfusion of whole blood is most appropriate in this setting, however the availability of blood group O whole blood with low levels (titers) of blood group antibodies (anti-A/B antibodies) is limited. Thus, products or methods for the manufacturing of LTOWB for use in massive transfusion may prove to be of significant clinical value in both civilian and military contexts.

The company's UBP-product has been tested at the University of Rochester Medical Center (U.S.) for this very purpose: to reduce anti-A/B antibody titers in blood group O whole blood.

The results1 are encouraging as they show that the UBP-product is effective in reducing anti-A/B antibody titers in whole blood units to near zero, without effecting other blood parameters as tested by the complete blood count or thromboelastography assays.

The authors conclude that the product “…could be readily and routinely used at blood collection center or transfusion facilities without extensive training. Preparation of LTOWB could have clinical value in massive transfusion in both civilian and military settings.”

(1)    Gupta G, Henrichs K, Nilsson K, Wagner S, Brown B, Masel D, Refaai M, Blumberg N; Reduction of Anti-A and Anti-B Isoagglutinin Titers of Group O Whole Blood Units with the Glycosorb® ABO Column Anesthesia & Analgesia. 133(3S):1-106, September 2021 (P 25).

The results will also be presented at the AABB congress in October 2021.
 

Contact
Johan Nilsson, Interim CEO, Glycorex Transplantation AB.
E-mail: info@glycorex.se, phone: 046-286 52 30

The information was submitted for publication, through the agency of the contact person, on September 24, 2021 17:15 CET.

Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.

News in swedish

Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting

Fri, Sep 24 2021, 15:15 GMT+0200 | Press release

The company has developed a CE-marked medical device for reduction of blood group A and blood group B specific antibodies (UBP-product).

Massive bleeding is one of the leading causes of death in severe trauma. Evidence is growing suggesting that transfusion of whole blood is most appropriate in this setting, however the availability of blood group O whole blood with low levels (titers) of blood group antibodies (anti-A/B antibodies) is limited. Thus, products or methods for the manufacturing of LTOWB for use in massive transfusion may prove to be of significant clinical value in both civilian and military contexts.

The company's UBP-product has been tested at the University of Rochester Medical Center (U.S.) for this very purpose: to reduce anti-A/B antibody titers in blood group O whole blood.

The results1 are encouraging as they show that the UBP-product is effective in reducing anti-A/B antibody titers in whole blood units to near zero, without effecting other blood parameters as tested by the complete blood count or thromboelastography assays.

The authors conclude that the product “…could be readily and routinely used at blood collection center or transfusion facilities without extensive training. Preparation of LTOWB could have clinical value in massive transfusion in both civilian and military settings.”

(1)    Gupta G, Henrichs K, Nilsson K, Wagner S, Brown B, Masel D, Refaai M, Blumberg N; Reduction of Anti-A and Anti-B Isoagglutinin Titers of Group O Whole Blood Units with the Glycosorb® ABO Column Anesthesia & Analgesia. 133(3S):1-106, September 2021 (P 25).

The results will also be presented at the AABB congress in October 2021.
 

Contact
Johan Nilsson, Interim CEO, Glycorex Transplantation AB.
E-mail: info@glycorex.se, phone: 046-286 52 30

The information was submitted for publication, through the agency of the contact person, on September 24, 2021 17:15 CET.

Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.

Subscribe to our releases

Choose categories

Contact information

The subscription service is provided by Cision.se and your information will be stored on their servers. The information will only be used to send you notifications when new releases are published. No personal information will be shared with any outside parties. Read more about our Privacy Policy.

News

Pontus Nobréus, CEO presenting Glycorex Transplantation on Redeye Growth Day june 2.
Presentationen >>

Download the presentationen >>

 

 

Pontus Nobréus, CEO presenting Glycorex Transplantation  BioStock Life Science Spring Summit on May 26
https://youtu.be/5fpTsNENiO8

Download the presentation >>

Glycorex Transplantation is a proud collaborator with The Hospital Clínic de Barcelona in Spain. It recently became the first hospital in Spain to carry out more than 1,000 living donor kidney transplants. To celebrate this milestone, a campaign called “A thousand transplants, a thousand stories” was launched to increase public awareness and encourage living donor kidney donations. https://www.clinicbarcelona.org/en/news/the-hospital-clinic-the-first-hospital-in-spain-to-carry-out-1-000-living-donor-kidney-transplants

REDEYE GROWTH DAY
Pontus Nobréus, CEO of Glycorex Transplantation will present at the Redeye Growth Day on June 2, 2021 at 08:50 CET.
Link to live streaming: https://www.redeye.se/events/808637/redeye-growth-day-2021

Glycorex Transplantation participates in the BioStock Life Science Spring Summit 2021. CEO Pontus Nobréus will present the company at the BioStock Life Science Spring Summit on May 26-27. For more information please visit: www.summit.biostock.se

Tomorrow, april 29th, Dr Guirado from Spain will discuss ABO incompatible kidney transplantations in a live Zoom seminar, arranged by our distributor in Mexcio, Ryse Médica and Sociedad Mexicana De Transplantes.

https://us02web.zoom.us/j/85789158554

Scheelevägen 27 | SE-223 63 Lund, Sweden

Phone: +46 46 286 52 30  | Fax: +46 46-286 52 39
E-mail: info@glycorex.com

Org.nr: 556519-7372

© 2021 Glycorex Transplantation AB. Registered office in Lund, Sweden . All rights reserved.